

# Helena W Rodbard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5357245/publications.pdf>

Version: 2024-02-01

27  
papers

2,914  
citations

471371

17  
h-index

501076

28  
g-index

28  
all docs

28  
docs citations

28  
times ranked

2611  
citing authors

#	ARTICLE	IF	CITATIONS
1	Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?. <i>Endocrinology, Diabetes and Metabolism</i> , 2022, 5, e00330.	1.0	9
2	Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412199592.	0.9	5
3	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108870.	1.1	4
4	Biosynthetic Human Insulin and Insulin Analogs. <i>American Journal of Therapeutics</i> , 2020, 27, e42-e51.	0.5	23
5	Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies. <i>Diabetes Care</i> , 2020, 43, 2713-2720.	4.3	15
6	Sotagliflozin added to optimized insulin therapy leads to <sc>HbA1c</sc> reduction without weight gain in adults with type 1 diabetes: A pooled analysis of <sc>inTandem1</sc> and <sc>inTandem2</sc>. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2089-2096.	2.2	9
7	Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. <i>American Journal of Managed Care</i> , 2020, 26, S335-S343.	0.8	14
8	Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 471-477.	2.4	17
9	Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. <i>Diabetes Care</i> , 2019, 42, 2272-2281.	4.3	225
10	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	4.3	249
11	Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis. <i>Diabetes Therapy</i> , 2019, 10, 177-188.	1.2	2
12	A comparative effectiveness study of degludec and insulin glargine 300 µU/mL in insulin-naïve patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1001-1009.	2.2	40
13	Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. <i>Advances in Therapy</i> , 2019, 36, 265-277.	1.3	26
14	Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. <i>Diabetes Care</i> , 2018, 41, 1009-1016.	4.3	143
15	The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1585-1592.	2.2	11
16	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. <i>Diabetes Care</i> , 2018, 41, 2552-2559.	4.3	177
17	The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, S2-33-S2-41.	2.4	19
18	Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2291-2301.	1.8	225

#	ARTICLE	IF	CITATIONS
19	The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, 171-180.	4.3	91
20	Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: a randomized, 18-week, open-label, phase 3 trial (onset 3). <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1389-1396.	2.2	40
21	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 864-876.	5.5	244
22	Comment on Edelman et al. AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes. <i>Diabetes Care</i> 2014;37:2132-2140. <i>Diabetes Care</i> , 2014, 37, e261-e262.	4.3	1
23	Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). <i>Diabetes Care</i> , 2014, 37, 2926-2933.	4.3	222
24	Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naïve patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 885-893.	5.5	295
25	Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 30-37.	5.5	74
26	Insulin Degludec Versus Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2464-2471.	4.3	305
27	Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 343-368.	0.6	423